Catalyst

Slingshot members are tracking this event:

Ionis Pharma (IONS) to complete Phase 1/2a study of ISIS-DMPKRx in Adults with Myotonic Dystrophy Type 1 by end of 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IONS

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1/2 Study, Isis-dmpkrx, Myotonic Dystrophy, Muscular Dystrophy, Isis-dmpkrx